MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
38.54
-1.64 (-4.08%)
May 13, 2025, 4:00 PM - Market closed

MLTX Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
34.5430.3222.3223.0121.66
Research & Development
136.22112.7731.842.0512.64
Operating Expenses
170.76143.0954.1265.0634.29
Operating Income
-170.76-143.09-54.12-65.06-34.29
Currency Exchange Gain (Loss)
0.040.040.150.33-0.07
Other Non Operating Income (Expenses)
23.2722.099.990.27-0
EBT Excluding Unusual Items
-147.46-120.96-43.98-64.47-34.37
Other Unusual Items
-----30
Pretax Income
-147.46-120.96-43.98-64.47-64.37
Income Tax Expense
0.370.280.090.040.01
Earnings From Continuing Operations
-147.83-121.24-44.08-64.51-64.37
Minority Interest in Earnings
2.622.318.0714.53-
Net Income
-145.21-118.94-36.01-49.97-64.37
Net Income to Common
-145.21-118.94-36.01-49.97-64.37
Shares Outstanding (Basic)
636349298
Shares Outstanding (Diluted)
636349298
Shares Change (YoY)
14.55%27.99%67.30%274.47%-
EPS (Basic)
-2.30-1.89-0.73-1.70-8.21
EPS (Diluted)
-2.30-1.89-0.73-1.70-8.21
Free Cash Flow
-140.12-117.11-43.06-55.91-42.27
Free Cash Flow Per Share
-2.22-1.86-0.88-1.90-5.39
EBITDA
-169.32-141.71-53.75-64.9-34.29
D&A For EBITDA
1.431.380.370.160.01
EBIT
-170.76-143.09-54.12-65.06-34.29
Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q